comprehensive -WSS

comprehensive

author：focus 2025-10-01 21:41:01 - browse：66

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： STAT Readout: Today's biotech news includes Sana and Amylyx

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

Female surgeons have lower rates of long

NEJM study link tiny plastics in blood vessels to heart problems

How to bring more disabled researchers into academia

How clinical AI models' predictive power can degrade over time

With psoriasis trial ahead, Alumis raises $259 million

explore

comprehensive

Wikipedia

Affirmative action in medical school literally saved lives

Cancer cells are shown to suck energy source from immune cells

At least 13 dead in Texas as scorching temps continue

STAT Readout: Today's biotech news includes Sana and Amylyx

Duchenne breakthrough therapy leaves behind pioneering families

European regulators consider appeal over Amylyx ALS drug

DIEP, the 'gold standard' of breast reconstruction, is under threat

Eight reasons why you should get an updated Covid vaccine

Novavax promises a turnaround & Lilly roils the obesity market

NEJM study link tiny plastics in blood vessels to heart problems

explore

How clinical AI models' predictive power can degrade over time

A fraught question for the kids of Alzheimer’s: Is it coming for us?

IVF, abortion rights issues kick off Biden’s State of the Union

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Life sciences deals on track to hit lowest point since 2017

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

explore

entertainment

focus

knowledge